133
Physiology and Pharmacology of thE BladdEr
filling has been demonstrated148 in normal, and |
3. |
Zinner NR, Koke SC, Viktrup L. Pharmacotherapy for |
||||
more clearly, rats with bladder hypertrophy sec- |
|
stress urinary incontinence: present and future options. |
||||
ondary to BOO. Capsaicin-induced DO was |
|
Drugs. 2004;64(14):1503-1516 |
||||
4. |
Andersson K-E, Chapple CR, Cardozo L, Cruz F, Hashim |
|||||
reduced by blocking NK1 receptor-expressing |
||||||
|
H,Michel MC,Tannenbaum C,Wein AJ.Pharmacological |
|||||
neurons in the spinal cord, using intrathecally |
|
|||||
|
treatment of urinary incontinence. In: Abrams P, |
|||||
administered substance P-saponin conjugate.149 |
|
Cardozo L, Khoury S, Wein A eds. Incontinence. 4th |
||||
Furthermore, blockade of spinal NK1 receptor |
|
International Consultation on Incontinence. Plymouth: |
||||
could suppress detrusor activity induced by |
|
Plymbridge Distributors; 2009 |
||||
dopamine receptor (L-DOPA) stimulation.104,105 |
5. |
Lincoln J, Burnstock, G. Autonomic innervation of the |
||||
Aprepitant, an NK-1 receptor antagonist used |
|
urinary bladder and urethra. In: Maggi CA, ed. The |
||||
|
Autonomic Nervous System.Vol. 6, Nervous Control of the |
|||||
for treatment of chemotherapy-induced nausea |
|
|||||
|
Urogenital System. London: Harwood Academic |
|||||
and vomiting,150 significantly improved symp- |
|
Publisher; 1993:33–68, chap. 2 |
||||
toms of OAB in postmenopausal women with a |
6. |
Zagorodnyuk VP, Costa M, Brookes SJ. Major classes of |
||||
history of urgency incontinence or mixed incon- |
|
sensory neurons to the urinary bladder. Auton Neurosci. |
||||
tinence (with predominantly urgency urinary |
7. |
2006;126–127:390-397 |
||||
incontinence), as shown in pilot randomized, |
Zagorodnyuk VP, Gibbins IL, Costa M, Brookes SJ, |
|||||
|
Gregory SJ. Properties of the major classes of mechano- |
|||||
placebo-controlled trial.151 |
Aprepitant |
signifi- |
|
|||
|
receptors in the guinea pig bladder. J Physiol. 2007; |
|||||
cantly decreased the average daily number of |
|
|||||
|
585:147-163 |
|||||
micturitions compared with placebo at 8 weeks. |
8. |
Iggo A. Tension receptors in the stomach and the urinary |
||||
The average daily number of urgency episodes |
|
bladder. J Physiol. 1955;128:593-607 |
||||
was also significantly reduced compared to pla- |
9. |
Kuru M. Nervous control of micturition. Physiol Rev. |
||||
cebo, and so were the average daily number of |
|
1965;45:425-494 |
||||
10. |
de Groat WC, Booth AM,Yoshimura N. Neurophysiology |
|||||
urgency incontinence and total urinary inconti- |
||||||
|
of micturition and its modification in animal models of |
|||||
nence episodes, although the difference was not |
|
|||||
|
human disease. In: Maggi CA, ed. Nervous Control of the |
|||||
statistically significant. Aprepitant was gener- |
|
Urogenital System. London: Harwood Academic; |
||||
ally well tolerated and the incidence of side |
|
1993:227-290 |
||||
effects, including |
dry mouth, was low. The |
11. |
Häbler HJ, Jänig W, Koltzenburg M. Activation of unmy- |
|||
results of this initial proof of concept study sug- |
|
elinated afferent fibres by mechanical stimuli and |
||||
|
inflammation of the urinary bladder in the cat. J Physiol. |
|||||
gest that NK-1 |
receptor |
antagonism |
holds |
|
||
|
1990;425:545-562 |
|||||
promise as a potential treatment approach for |
|
|||||
12. |
Fall M, Lindstrom S, Mazieres L. A bladder-to-bladder |
|||||
OAB/DO. |
|
|
|
|
cooling reflex in the cat. J Physiol. 1990;427:281-300 |
|
|
|
|
|
13. |
Andersson KE, Wein AJ. Pharmacology of the lower uri- |
|
Summary |
|
|
|
|
nary tract: basis for current and future treatments of |
|
|
|
|
|
urinary incontinence. Pharmacol Rev. December 2004; |
||
|
|
|
|
|
||
|
|
|
|
|
56(4):581-631 |
|
To effectively control bladder activity, and to |
14. |
Burnstock G. Purinergic signalling in lower urinary |
||||
|
tract. In: Abbracchio MP, Williams MP, eds. Purinergic |
|||||
treat urinary incontinence, identification of |
|
and Pyrimidinergic Signalling I Molecular, Nervous and |
||||
suitable targets for pharmacological interven- |
|
Urogenitary System Function. Berlin: Springer; 2001:151, |
||||
tion is necessary. Such targets may be found in |
15. |
423–515 |
||||
the central nervous system (CNS) or peripher- |
Thor KB, Donatucci C. Central nervous system control |
|||||
|
of the lower urinary tract: new pharmacological |
|||||
ally. Drugs, specifically directed for control of |
|
|||||
|
approaches to stress urinary incontinence in women. |
|||||
bladder activity are under development and will |
|
|||||
|
J Urol. 2004;172(1):27-33 |
|||||
hopefully lead to improved treatment of urinary |
16. |
Yoshimura N, Kaiho Y, Miyazato M, et al. Therapeutic |
||||
incontinence. |
|
|
|
|
receptor targets for lower urinary tract dysfunction. |
|
|
|
|
|
|
Naunyn Schmiedebergs Arch Pharmacol. 2008; 377(4–6): |
|
|
|
|
|
|
437-448 |
|
References |
|
|
|
17. |
Andersson K-E. Bladder activation: afferent mecha- |
|
|
|
|
|
nisms. Urology. 2002;59(5 Suppl 1):43-50 |
||
|
|
|
|
18. |
Birder LA, Kanai AJ, de Groat WC, et al. Vanilloid recep- |
|
1. Andersson KE, Arner A. Urinary bladder contraction |
|
tor expression suggests a sensory role for urinary |
||||
and relaxation: physiology and pathophysiology. Physiol |
|
bladder epithelial cells. Proc Natl Acad Sci USA. 6, |
||||
Rev. 2004;84(3):935-986 |
|
|
|
2001;98(23):13396-13401 |
||
2. Fowler CJ, Griffiths D, de Groat WC. The neural |
19. |
Birder LA, Nakamura Y, Kiss S, et al. Altered urinary |
||||
control of micturition. Nat Rev Neurosci. 2008;9(6): |
|
bladder function in mice lacking the vanilloid receptor |
||||
453-466 |
|
|
|
|
TRPV1. Nat Neurosci. 2002;5(9):856-860 |
|
134
Practical Urology: EssEntial PrinciPlEs and PracticE
20.Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002;90(1):118-129
21.Sui GP, Wu C, Fry CH. Electrical characteristics of subu-
rothelial cells isolated from the human bladder.
J Urol. 2004;171(2 Pt 1):938-943
22.Birder and de Groat, 2007 (Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction., Nat Clin Pract Urol. 2007 Jan;4(1):46-54)
23.Pandita RK, Andersson KE. Intravesical adenosine triphosphate stimulates the micturition reflex in awake, freely moving rats. J Urol. 2002;168(3):1230-1234
24.Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407(6807): 1011-1015
25.Vlaskovska M, Kasakov L, Rong W, et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci. 2001;21(15):5670-5677
26.Fovaeus M, Fujiwara M, Hogestatt ED, Persson K, Andersson KE. A non-nitrergic smooth muscle relaxant factor released from rat urinary bladder by muscarinic receptor stimulation. J Urol. 1999;161(2): 649-653
27.Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129(3):416-419
28.Hashitani H, Brading AF, Suzuki H. Correlation between spontaneous electrical, calcium and mechanical activity in detrusor smooth muscle of the guinea-pig bladder. Br J Pharmacol. 2004;141(1):183-193
29.Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet. 2001; 358(9279):401-403
30.Gillespie JI. A developing view of the origins of urgency: the importance of animal models. BJU Int. 2005;96 (Suppl 1):22-28
31.Kinder RB, Mundy AR. Pathophysiology of idiopathic detrusor instability and detrusor hyper-reflexia. An in vitro study of human detrusor muscle. Br J Urol. 1987;60(6):509-515
32.Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50(6A Suppl):57-67; discussion 68-73
33.Mills IW, Greenland JE, McMurray G, et al. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol. 2000; 163:646-651
34.Turner WH, Brading AF. Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol Ther. 1997; 75(2):77-110
35.Stevens LA, Chapple CR, Chess-Williams R. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol. 2007;52(2):531-538
36.Wu C, Sui GP, Fry CH. Purinergic regulation of guinea pig suburothelial myofibroblasts. J Physiol. 2004;559 (Pt 1):231-243
37.Fry CH, Sui GP, Kanai AJ, Wu C. The function of suburothelial myofibroblasts in the bladder. Neurourol Urodyn. 2007;26(6 Suppl):914-919
38.Ikeda Y, Kanai A. Urotheliogenic modulation of intrinsic activity in spinal cord-transected rat bladders: role of mucosal muscarinic receptors. Am J Physiol Ren Physiol. 2008;295(2):F454-F461
39.Sui GP, Wu C, Roosen A, Ikeda Y, Kanai AJ, Fry CH. Modulation of bladder myofibroblast activity: implications for bladder function. Am J Physiol Ren Physiol. 2008;295(3):F688-F697
40.Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J. On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int. 2009;103(10): 1324-1333
41.Caulfield MP, Birdsall NJM. International Union of Pharmacology: XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50: 279-290
42.Sigala S, Mirabella G, Peroni A, et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology. 2002;60(4):719-725
43.Bschleipfer T, Schukowski K,Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80(24–25):2303-2307
44.Yamaguchi O, Shishido K, Tamura K, et al. Evaluation of mRNAs encoding muscarinicreceptor subtypes in human detrusor muscle. J Urol. 1996;156:1208-1213
45.Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996;48:531-565
46.Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 1999;64(6–7):419-428
47.Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol. 2002;22(3):133-145
48.Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83(5): 259-269
49.Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. June 2004;309(3):1148-1153
50.Jezior JR, Brady JD, Rosenstein DI, McCammon KA, Miner AS, Ratz PH. Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels. Br J Pharmacol. 2001;134(1):78-87
51.Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol. 2003; 138(5):757-766
52.Andersson K-E. Detrusor contraction – focus on muscarinic receptors. Scand J Urol Nephrol Suppl. 2004;215: 54-57
53.Hegde SS, Choppin A, Bonhaus D, et al. Functional role of M-2 and M-3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol. 1997;120:1409-1418
54.Kotlikoff MI, Dhulipala P, Wang YX. M2 signaling in smooth muscle cells. Life Sci. 1999;64(6–7):437-442
55.Nakamura T, Kimura J, Yamaguchi O. Muscarinic M2 receptors inhibit Ca2+-activated K+ channels in rat bladder smooth muscle. Int J Urol. 2002;9(12):689-696
135
Physiology and Pharmacology of thE BladdEr
56.Bonev AD, Nelson MT. Muscarinic inhibition of ATPsensitive K+ channels by protein kinase C in urinary
bladder smooth muscle. Am J Physiol. 1993;265 (6 Pt 1):C1723-C1728
57.Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol. 1998;275: R1654-R1660
58.Braverman A, Legos J, Young W, Luthin G, Ruggieri M. M2 receptors in genito-urinary smooth muscle pathology. Life Sci. 1999;64:429-436
59.Braverman AS, Tallarida RJ, Ruggieri MR Sr. Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol. September 2002; 283(3):R663-R668
60.Braverman AS, Ruggieri MR Sr. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am J Physiol Regul Integr Comp Physiol. 2003;285(3):R701-R708
61.Pontari MA, Braverman AS, Ruggieri MR Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol. 2004;286(5):R874-R880
62.D’Agostino G, Bolognesi ML, Lucchelli A, et al. Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptor subtype. Br J Pharmacol. 2000;129(3):493-500
63.Somogyi GT, de Groat WC. Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. 1999; 64(6–7):411-418
64.Somogyi GT, Zernova GV,Yoshiyama M, Rocha JN, Smith CP, de Groat WC. Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury. Neurochem Int. 2003;43(1):73-77
65.Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, de Miguel F. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol. 2006;176(4 Pt 1):1673-1678
66.Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radiolig-and binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144(8):1089-1099
67.Mukerji G, Yiangou Y, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006; 176(1):367-373
68.Grol S,Essers PB,van Koeveringe GA,Martinez-Martinez P, de Vente J, Gillespie JI. M(3) muscarinic receptor expression on suburothelial interstitial cells. BJU Int. 11, 2009 [Epub ahead of print]
69.Wakabayashi Y, Tomoyoshi T, Fujimiya M, Arai R, Maeda T. Substance P-containing axon terminals in the mucosa of the human urinary bladder: pre-embedding immunohistochemistry using cryostat sections for electron microscopy. Histochemistry. 1993;100(6):401-407
70.Persson K, Alm P, Johansson K, Larsson B, Andersson KE. Co-existence of nitrergic, peptidergic and
acetylcholine esterase-positive nerves in the pig lower urinary tract. J Auton Nerv Syst. 1995;52(2–3):225-236
71.Gabella G, Davis C. Distribution of afferent axons in the bladder of rats. J Neurocytol. 1998;27(3):141-155
72.Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes–a possible sensory mechanism? J Physiol. 1997;505(Pt 2):503-511
73.Birder LA, Barrick SR, Roppolo JR, et al. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am J Physiol Ren Physiol. 2003;285(3):F423-F429
74.Kullmann FA, Artim DE, Birder LA, de Groat WC. Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity. J Neurosci. 2008;28(8):1977-1987
75.Yoshida M, Inadome A, Maeda Y, et al. Non-neuronal cholinergic system in human bladder urothelium. Urology. 2006;67(2):425-430
76.Hanna-Mitchell AT, Beckel JM, Barbadora S, Kanai AJ, de Groat WC, Birder LA. Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci. 2007;80(24–25): 2298-2302
77.Beckel JM, Kanai A, Lee SJ, de Groat WC, Birder LA. Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am J Physiol Ren Physiol. 2006;290(1):F103-F110
78.Malloy BJ, Price DT, Price RR, et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol. 1998; 160:937-943
79.Michel MC, Vrydag W. Alpha1-, alpha2and beta-adre- noceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88-S119
80.Andersson KE, Gratzke C. Pharmacology of alpha1adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007; 4(7):368-378
81.Nomiya M,Yamaguchi O.A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes andtheirfunctionalrolesinhumannormalandobstructed bladders. J Urol. 2003;170(2 Pt 1):649-653
82.Bouchelouche K, Andersen L, Alvarez S, Nordling J, Bouchelouche P. Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrener- gic receptor antagonist tamsulosin. J Urol. 2005;173(2): 657-661
83.Das AK, Leggett RE, Whitbeck C, et al. Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn. 2002;21:160-166
84.Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 1993;45:253-308
85.Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4–6):473-481
86.Badawi JK, Seja T, Uecelehan H, et al. Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. Urology. 2007;69(4):785-790
136
Practical Urology: EssEntial PrinciPlEs and PracticE
87.Leon LA, Hoffman BE, Gardner SD, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2- [[(2R)-2- (3-chlorophenyl)-2-hydroxyethyl]amino]pro- pyl]-1, 3-benzodioxole-2, 2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2008;326(1):178-185
88.Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98(6):1310-1314
89.Andersson K-E. Pathways for relaxation of detrusor smooth muscle. In: Baskin LS, Hayward SW, eds.
Advances in Bladder Research. New York: Kluwer Academic/Plenum; 1999:241-252
90.Uchida H, Shishido K, Nomiya M, Yamaguchi O. Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors. Eur J Pharmacol. 22, 2005;518 (2–3):195-202
91.Frazier EP, Peters SL, Braverman AS, Ruggieri MR Sr, Michel MC. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377(4–6):449-462
92.Takemoto J, Masumiya H, Nunoki K, et al. Potentiation of potassium currents by beta-adrenoceptor agonists in human urinary bladder smooth muscle cells: a possible electrical mechanism of relaxation. Pharmacology. 2008;81(3):251-258
93.Hristov KL, Cui X, Brown SM, Liu L, Kellett WF, Petkov GV.
Stimulation of beta3-adrenoceptors |
relaxes |
rat |
urinary bladder smooth muscle via |
activation |
of |
the large-conductance Ca2+-activated |
K+ channels. |
|
Am J Physiol Cell Physiol. 2008;295(5):C1344-C1353
[Epub September 17, 2008]
94.Fujimura T, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol. 1999;161(2): 680-685
95.Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol. 2001;166(3): 1142-1147
96.Takeda H, Yamazaki Y, Igawa Y, et al. Effects of beta(3)- adrenoceptor stimulation on prostaglandin E(2)- induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn. 2002; 21(6):558-565
97.Kaidoh K, Igawa Y, Takeda H, et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol. 2002;168(3):1247-1252
98.Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323(1):202-209
99.Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs. 2007;16(7):999-1007
100.Takasu T, Ukai M, Sato S, et al. Effect of (R)-2- (2-amin- othiazol-4-yl)-4’- {2-[(2-hydroxy-2-phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective beta3adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642-647 [Epub February 9, 2007]
101.Chapple CR,Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows novel B3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl. 2008;7(3):239. abstract 674
102.Everaerts W, Gevaert T, Nilius B, De Ridder D. On the origin of bladder sensing: Tr(i)ps in urology. Neurourol Urodyn. 2008;27(4):264-273
103.Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction.
Nat Clin Pract Urol. 2007;4(1):46-54
104.Ishizuka O, Mattiasson A, Andersson K-E. Urodynamic effects of intravesical resiniferatoxin and capsaicin in conscious rats with and without outflow obstruction. J Urol. 1995;154:611-616
105.Ishizuka O, Mattiasson A, Andersson KE. Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats. J Urol. 1995;154(4):1548-1551
106.Szallazi A, Blumberg PM. Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain. 1996;68(2–3):195-208
107.Kuo H-C. Inhibitory effect of capsaicin on detrusor contractility: further study in the presence of ganglionic blocker and neurokinin receptor antagonist in the rat urinary bladder. Urol Int. 1997;59:95-101
108.Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007;26(6 Suppl): 928-933
109.Truss MC, Stief CG, Uckert S, et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol. 2001; 19:344-350
110.Longhurst PA, Briscoe JA, Rosenberg DJ, Leggett RE. The role of cyclic nucleotides in guinea-pig bladder contractility. Br J Pharmacol. 1997;121(8):1665-1672
111.Kaiho Y, Nishiguchi J, Kwon DD, et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int. 2008;101(5):615-620
112.Nishiguchi J, Kwon DD, Kaiho Y, et al. Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor. BJU Int. 2007;99(3):680-686
113.Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol. 2005;5(3):238-244
114.Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90(9):836-839
115.McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007; 177(4):1401-1407
137
Physiology and Pharmacology of thE BladdEr
116.McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177(3):1071-1077
117.Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E.A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53(6):1236-1244
118.de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol. 2001;41: 691-721
119.Murray KH, Feneley RC. Endorphins-a role in lower urinary tract function? The effect of opioid blockade on the detrusor and urethral sphincter mechanisms. Br J Urol. 1982;54(6):638-640
120.Dray A, Nunan L, Wire W. Naloxonazine and opioidinduced inhibition of reflex urinary bladder contractions. Neuropharmacology. 1987;26(1):67-74
121.Herman RM, Wainberg MC, delGiudice PF, Willscher MK. The effect of a low dose of intrathecal morphine on impaired micturition reflexes in human subjects with spinal cord lesions. Anesthesiology. 1988; 69(3):313-318
122.Kieffer BL. Opioids: first lessons from knockout mice.
Trends Pharmacol Sci. 1999;20(1):19-26
123.Raffa RB, Friderichs E. The basic science aspect on tramadol hydrochloride. Pain Rev. 1996;3:249-271
124.Pandita RK, Pehrson R, Christoph T, Friderichs E, Andersson KE. Actions of tramadol on micturition in awake, freely moving rats. Br J Pharmacol. 2003; 139(4):741-748
125.Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol. 2006;61(4): 456-463
126.Ranson RN, Dodds AL, Smith MJ, Santer RM, Watson AH. Age-associated changes in the monoaminergic innervation of rat lumbosacral spinal cord. Brain Res. 16, 2003;972(1–2):149-158
127.Thor KB, Blitz-Siebert A, Helke CJ. Autoradiographic localization of 5hydroxytryptamine1A, 5-hydroxy- tryptamine1B and 5-hydroxytryptamine1C/2 binding sites in the rat spinal cord. Neuroscience. 1993;5(1): 235-252
128.de Groat WC. Influence of central serotonergic mechanisms on lower urinary tract function. Urology. 2002;59(5 Suppl 1):30-36
129.McMahon SB, Spillane K. Brain stem influences on the parasympathetic supply to the urinary bladder of the cat. Brain Res. 25, 1982;234(2):237-249
130.Sugaya K, Ogawa Y, Hatano T, Koyama Y, Miyazato T, Oda M. Evidence for involvement of the subcoeruleus nucleus and nucleus raphe magnus in urine storage and penile erection in decerebrate rats. J Urol. 1998;159(6):2172-2176
131.Katofiasc MA, Nissen J, Audia JE, et al. Comparison of the effects of serotonin selective norepinephrine selective, and dual serotonin and norepinephrine reuptake
inhibitors on lower urinary tract function in cats. Life Sci. 2002;71(11):1227
132. Thor K, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat.
JPharmacol Exp Ther. 1995;274(2):1014
133.Fraser MO, Chancellor MB. Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int. 2003;91(8):743
134.Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007;100(2):337
135.Chebib M, Johnston GAR. The ‘ABC’ of GABA receptors: a brief review. Clin Exp Pharmacol Physiol. 1999;26(11):937-940
136.Igawa Y, Mattiasson A, Andersson KE. Effects of GABAreceptor stimulation and blockade on micturition in normal rats and rats with bladder outflow obstruction.
JUrol. 1993;150(2 Pt 1):537-542
137.Pehrson R,LehmannA,Andersson KE.Effects of gammaaminobutyrate B receptor modulation on normal micturition and oxyhemoglobin induced detrusor overactivity in female rats. J Urol. 2002; 168(6):2700-2705
138.Maggi CA, Santicioli P, Giuliani S, et al. The effects of baclofen on spinal and supraspinal micturition reflexes in rats. Naunyn Schmiedebergs Arch Pharmacol. 1987;336(2):197-203
139.Malcangio M, Bowery NG. GABA and its receptors in the spinal cord. Trends Pharm Sci. 1996;17(12):457-462
140.Coggeshall RE, Carlton SM. Receptor localization in the mammalian dorsal horn and primary afferent neurons.
Brain Res Brain Res Rev. 1997;24(1):28-66
141.Taylor MC, Bates CP. A double-blind crossover trial of baclofen–a new treatment for the unstable bladder syndrome. Br J Urol. 1979;51(6):504-505
142.Maneuf YP, Gonzalez MI, Sutton KS, Chung FZ, Pinnock RD, Lee K. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci. 2003;60(4):742-750
143.Carbone A, Palleschi G, Conte A, Bova G, Iacovelli E, Bettolo RM.Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol. 2006;29(4):206-214.
144.Kim YT, Kwon DD, Kim J, Kim DK, Lee JY, Chancellor MB. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol. 2004; 30(4):275-278
145.Lecci A, Maggi CA. Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept. 15, 2001;101(1–3):1-18
146.Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience. 2003;116(3):761-773
147.Covenas R, Martin F, Belda M, et al. Mapping of neuro- kinin-like immunoreactivity in the human brainstem. BMC Neurosci. 2003;4(1):3
148.Ishizuka O, Igawa Y, Lecci A, Maggi CA, Mattiasson A, Andersson KE.Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction. Br J Pharmacol. 1994;113(1):111-116
138
Practical Urology: EssEntial PrinciPlEs and PracticE
149.Seki S, Erickson KA, Seki M, et al. Elimination of rat spinal neurons expressing neurokinin 1 receptors reduces bladder overactivity and spinal c-fos expression induced by bladder irritation. Am J Physiol Ren Physiol. March 2005;288(3):F466-F473
150.Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39(1):77-85
151.Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor
antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol. 2006;176(6 Pt 1):2535-2540
152.Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. 2004;93(4):478-483
153.Gillespie JI. Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int. 2004;93(9):1325-1332